{"id":"https://openalex.org/W2096861436","doi":"https://doi.org/10.1158/1535-7163.mct-10-0876","title":"An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2\u2013Dependent Angiogenesis without Affecting Ligand Binding","display_name":"An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2\u2013Dependent Angiogenesis without Affecting Ligand Binding","publication_year":2011,"publication_date":"2011-03-10","ids":{"openalex":"https://openalex.org/W2096861436","doi":"https://doi.org/10.1158/1535-7163.mct-10-0876","mag":"2096861436","pmid":"https://pubmed.ncbi.nlm.nih.gov/21388971"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-10-0876","doi":"https://doi.org/10.1158/1535-7163.mct-10-0876","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0876","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.25405/ncl.34190280","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001053254","display_name":"Jane Kendrew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jane Kendrew","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032576859","display_name":"Cath Eberlein","orcid":"https://orcid.org/0000-0002-7357-7789","observed_orcids":["https://orcid.org/0000-0002-7357-7789"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Cath Eberlein","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073338549","display_name":"Brad Hedberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Brad Hedberg","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014495669","display_name":"Karen McDaid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karen McDaid","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027141514","display_name":"Neil R. Smith","orcid":"https://orcid.org/0000-0002-0023-4398","observed_orcids":["https://orcid.org/0000-0002-0023-4398"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Neil R. Smith","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048485800","display_name":"Hazel M. Weir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Hazel M. Weir","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058765817","display_name":"Stephen R. Wedge","orcid":"https://orcid.org/0000-0002-3644-6157","observed_orcids":["https://orcid.org/0000-0002-3644-6157"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen R. Wedge","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108761410","display_name":"David C. Blakey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David C. Blakey","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034901985","display_name":"Ian N. Foltz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian Foltz","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013945103","display_name":"Joe Q. Zhou","orcid":"https://orcid.org/0000-0003-4059-7190","observed_orcids":["https://orcid.org/0000-0003-4059-7190"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Joe Zhou","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042319748","display_name":"Jaspal S. Kang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jaspal S. Kang","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044054725","display_name":"Simon T. Barry","orcid":"https://orcid.org/0000-0002-8511-0588","observed_orcids":["https://orcid.org/0000-0002-8511-0588"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon T. Barry","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Bioscience, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom; and 2Amgen (formerly Abgenix), Burnaby, British Columbia, Canada","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I105036370"],"apc_list":null,"apc_paid":null,"fwci":1.7406,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.84455892,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"10","issue":"5","first_page":"770","last_page":"783"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.9929999709129333},{"id":"https://openalex.org/keywords/immunoglobulins","display_name":"immunoglobulins","score":0.3310000002384186},{"id":"https://openalex.org/keywords/vegf-a","display_name":"VEGF-A","score":0.6639999747276306},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.8930000066757202},{"id":"https://openalex.org/keywords/vegfr2-phosphorylation","display_name":"VEGFR2 phosphorylation","score":0.8320000171661377},{"id":"https://openalex.org/keywords/tumor-growth","display_name":"tumor growth","score":0.4819999933242798},{"id":"https://openalex.org/keywords/endothelial-tube-formation","display_name":"endothelial tube formation","score":0.7900000214576721}],"concepts":[{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.8496636152267456},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5937502980232239},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.5327489376068115},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5053473114967346},{"id":"https://openalex.org/C14858245","wikidata":"https://www.wikidata.org/wiki/Q18028241","display_name":"Kinase insert domain receptor","level":5,"score":0.502631664276123},{"id":"https://openalex.org/C116569031","wikidata":"https://www.wikidata.org/wiki/Q899107","display_name":"Ligand (biochemistry)","level":3,"score":0.47048619389533997},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.452062726020813},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4455632269382477},{"id":"https://openalex.org/C107824862","wikidata":"https://www.wikidata.org/wiki/Q616005","display_name":"Binding site","level":2,"score":0.4113503098487854},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.4106106460094452},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4023187458515167},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.38404640555381775},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3815872371196747},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.36346375942230225},{"id":"https://openalex.org/C146285616","wikidata":"https://www.wikidata.org/wiki/Q7916455","display_name":"Vascular endothelial growth factor A","level":4,"score":0.3324623703956604},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.24169716238975525},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.2275623381137848},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000918","descriptor_name":"Antibody Specificity","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002460","descriptor_name":"Cell Line","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":true},{"descriptor_ui":"D012867","descriptor_name":"Skin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013552","descriptor_name":"Swine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017434","descriptor_name":"Protein Structure, Tertiary","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018919","descriptor_name":"Neovascularization, Physiologic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D042783","descriptor_name":"Endothelial Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D042783","descriptor_name":"Endothelial Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1158/1535-7163.mct-10-0876","doi":"https://doi.org/10.1158/1535-7163.mct-10-0876","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0876","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:21388971","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21388971","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1010.4806","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1010.4806","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/molcanther/10/5/770.full.pdf","raw_type":"text"},{"id":"doi:10.25405/ncl.34190280","doi":"https://doi.org/10.25405/ncl.34190280","is_oa":true,"landing_page_url":"https://doi.org/10.25405/ncl.34190280","pdf_url":null,"source":{"id":"https://openalex.org/S4306402485","display_name":"Newcastle University ePrints (Newcastle Univesity)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I84884186","host_organization_name":"Newcastle University","host_organization_lineage":["https://openalex.org/I84884186"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},{"id":"doi:10.25405/ncl.34190280.v1","doi":"https://doi.org/10.25405/ncl.34190280.v1","is_oa":true,"landing_page_url":"https://doi.org/10.25405/ncl.34190280.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402485","display_name":"Newcastle University ePrints (Newcastle Univesity)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I84884186","host_organization_name":"Newcastle University","host_organization_lineage":["https://openalex.org/I84884186"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.25405/ncl.34190280","doi":"https://doi.org/10.25405/ncl.34190280","is_oa":true,"landing_page_url":"https://doi.org/10.25405/ncl.34190280","pdf_url":null,"source":{"id":"https://openalex.org/S4306402485","display_name":"Newcastle University ePrints (Newcastle Univesity)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I84884186","host_organization_name":"Newcastle University","host_organization_lineage":["https://openalex.org/I84884186"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W157457955","https://openalex.org/W1756949381","https://openalex.org/W1868766650","https://openalex.org/W1875554126","https://openalex.org/W1967841898","https://openalex.org/W1969328947","https://openalex.org/W1971054825","https://openalex.org/W1971643696","https://openalex.org/W1980725734","https://openalex.org/W1980813769","https://openalex.org/W1995840246","https://openalex.org/W1996372431","https://openalex.org/W2000043742","https://openalex.org/W2000064849","https://openalex.org/W2014148719","https://openalex.org/W2042349690","https://openalex.org/W2063249586","https://openalex.org/W2067684732","https://openalex.org/W2081887573","https://openalex.org/W2091774189","https://openalex.org/W2097373408","https://openalex.org/W2102056525","https://openalex.org/W2105677187","https://openalex.org/W2111628999","https://openalex.org/W2112940666","https://openalex.org/W2117713501","https://openalex.org/W2118559000","https://openalex.org/W2123334268","https://openalex.org/W2128056949","https://openalex.org/W2128556846","https://openalex.org/W2139135964","https://openalex.org/W2140765540","https://openalex.org/W2156250197","https://openalex.org/W2160108544","https://openalex.org/W2165003903","https://openalex.org/W2166259130","https://openalex.org/W2166788033","https://openalex.org/W2168215545","https://openalex.org/W6606281253","https://openalex.org/W6637994761","https://openalex.org/W6639195840","https://openalex.org/W6677621843","https://openalex.org/W6678456434"],"related_works":["https://openalex.org/W7099023645","https://openalex.org/W2886507808","https://openalex.org/W2566374557","https://openalex.org/W2047556120","https://openalex.org/W3139165641","https://openalex.org/W2121268199","https://openalex.org/W2070807808","https://openalex.org/W3176943569","https://openalex.org/W2799894070","https://openalex.org/W2097964779"],"abstract_inverted_index":{"Inhibition":[0],"of":[1,49,59,77,79,86,138,143,163,182,204,213,218],"VEGFR-2":[2,14,26,41,50,66,96,128,139,202,214],"signaling":[3,15,42,215],"reduces":[4],"angiogenesis":[5,153,183,189,219],"and":[6,51,88,108,133,161,166,191,216,222],"retards":[7],"tumor":[8],"growth.":[9],"Current":[10],"biotherapeutics":[11],"that":[12,39,93,115],"inhibit":[13],"by":[16,30,43],"either":[17],"sequestering":[18],"VEGF":[19,23,32],"ligand":[20,60,119,206],"or":[21],"inhibiting":[22],"binding":[24,44,89,105,120,207],"to":[25,45,56,106],"may":[27],"be":[28],"compromised":[29],"high":[31,125],"concentrations.":[33],"Here":[34],"we":[35,81],"describe":[36],"a":[37,63,84,124,151,171,178,186,193],"biotherapeutic":[38],"targets":[40],"Ig":[46,97],"domains":[47,98],"4-7":[48],"therefore":[52],"has":[53,100,123],"the":[54,75,118,205],"potential":[55],"work":[57],"independently":[58],"concentration.":[61],"33C3,":[62,80],"fully":[64],"human":[65,187,194],"antibody,":[67],"was":[68],"generated":[69],"using":[70],"XenoMouse":[71],"technology.":[72],"To":[73],"elucidate":[74],"mechanism":[76],"action":[78],"have":[82],"used":[83],"number":[85,162],"competition":[87],"assays.":[90],"We":[91],"show":[92,200],"33C3":[94,122,155,176],"binds":[95],"4-7,":[99],"no":[101],"impact":[102],"on":[103],"VEGF-A":[104,135],"VEGFR-2,":[107],"does":[109],"not":[110],"compete":[111],"with":[112,140],"an":[113,141],"antibody":[114],"interacts":[116],"at":[117],"site.":[121],"affinity":[126],"for":[127],"(K(D)":[129],"<":[130],"1":[131],"nmol/L)":[132],"inhibits":[134,157],"induced":[136],"phosphorylation":[137],"IC(50)":[142],"99":[144],"\u00b1":[145],"3":[146],"ng/mL.":[147],"In":[148,174],"vitro,":[149],"in":[150,170,184,192,210,220,223],"2D":[152],"assay,":[154],"potently":[156],"both":[158,185],"tube":[159],"length":[160],"branch":[164],"points,":[165],"endothelial":[167,188],"tubule":[168],"formation":[169],"3D":[172],"assay.":[173],"vivo,":[175],"is":[177],"very":[179],"effective":[180],"inhibitor":[181],"assay":[190],"skin":[195],"chimera":[196],"model.":[197],"These":[198],"data":[199],"targeting":[201],"outside":[203],"domain":[208],"results":[209],"potent":[211],"inhibition":[212,217],"vitro":[221],"vivo.":[224]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}